Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Characterizing the Multiple Myeloma Bone Marrow Microenvironment at the Single-Cell Level in a Preclinical Model

Raquel Lopes, Ana C Queirós, Diana Lourenço, Rita C Acúrcio, Bjarne Bogen, Karine Serre, Helena F Florindo, Cristina João

Blood (2024) 144 (Supplement 1): 4664.

https://doi.org/10.1182/blood-2024-205433

Published: 2024

Journal Articles

IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model

Brandon D. Ng, Adhithi Rajagopalan, Anastasia I. Kousa, Jacob S. Fischman, Sophia Chen, Alyssa Massa, Harold K. Elias, Dylan Manuele, Michael Galiano, Andri L. Lemarquis, Alexander P. Boardman, Susan DeWolf, Jonah Pierce, Bjarne Bogen, Scott E. James, Marcel R. M. van den Brink

Blood (2024) 144 (2): 171–186.

https://doi.org/10.1182/blood.2023022293

Published: 2024

Includes: Supplemental data

Journal Articles

Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of Multiple Myeloma

Selma Bekri, PhD, Reunet Rodney-Sandy, BS, Diana Gruenstein, BS, Bjarne Bogen, MD PhD, Daniel Levey, PhD, Hearn Jay Cho, MD

Blood (2018) 132 (Supplement 1): 1947.

https://doi.org/10.1182/blood-2018-99-117129

Published: 2018

Journal Articles

Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model

Selma Bekri, PhD, Mohamed Uduman, PhD, Diana Gruenstein, BS, Anna Huo-Chang Mei, MS, Kaity Tung, BS, Reunet Rodney-Sandy, BS, Bjarne Bogen, MD PhD, Jennifer Buell, PhD, Robert Stein, MD PhD, Kaitlin Doherty, Mark Findeis, PhD, Benjamin Morin, PhD, Bishnu Joshi, PhD, Antoine Tanne, PhD, John Castle, PhD, Daniel Levey, PhD, Hearn Jay Cho, MD PhD

Blood (2017) 130 (Supplement 1): 1868.

https://doi.org/10.1182/blood.V130.Suppl_1.1868.1868

Published: 2017

Journal Articles

Targeted Remodeling of the Tumor Microenvironment Via Mechanical Stimulation Defines a Novel Therapeutic Strategy in Myeloma Bone Disease

Fani Ziouti, Maximilian Rummler, Anne Seliger, Andreas Brandl, PhD, Andreas Beilhack, MD, Bjarne Bogen, MD PhD, Maureen Lynch, PhD, Franz Jakob, MD, Regina Ebert, PhD, Bettina Willie, PhD, Franziska Jundt, MD

Blood (2017) 130 (Supplement 1): 1778.

https://doi.org/10.1182/blood.V130.Suppl_1.1778.1778

Published: 2017

Journal Articles

CSF1R-Inhibition and Reduction of Macrophages Delays Multiple Myeloma Growth in a Non-T-Cell-Dependent Manner

Fredrik H. Schjesvold, MD, Ole Audun Haabeth, MD PhD, Bjarne Bogen, MD PhD, Anders Tveita, MD PhD

Blood (2014) 124 (21): 5717.

https://doi.org/10.1182/blood.V124.21.5717.5717

Published: 2014

Journal Articles

Targeting Notch and Hedgehog Embryonic Signaling Pathways Has Potent Anti-Tumor Activity in Myeloma and Is Effective in Myeloma Bone Disease.

Rolf Schwarzer, Nicole Schünemann, David M Wong, Bjarne Bogen, Kurt Bommert, Bernd Dörken, MD, Rudolf Manz, Franziska Jundt, MD

Blood (2012) 120 (21): 2938.

https://doi.org/10.1182/blood.V120.21.2938.2938

Published: 2012

Journal Articles

Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice

Kristina Berg Lorvik, Bjarne Bogen, Alexandre Corthay

Blood (2012) 119 (9): 2176–2177.

https://doi.org/10.1182/blood-2011-10-388892

Published: 2012

Journal Articles

Lymphoma invisibility–vaccination–attack?

Bjarne Bogen

Blood (2011) 117 (5): 1437–1438.

https://doi.org/10.1182/blood-2010-11-318469

Published: 2011

Journal Articles

Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences

Agnete Brunsvik Fredriksen, Bjarne Bogen

Blood (2007) 110 (6): 1797–1805.

https://doi.org/10.1182/blood-2006-06-032938

Published: 2007

Includes: Supplemental data

Journal Articles

Therapeutic effect of idiotype-specific CD4 + T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies

Katrin U. Lundin, Peter O. Hofgaard, Hilde Omholt, Ludvig A. Munthe, Alexandre Corthay, Bjarne Bogen

Blood (2003) 102 (2): 605–612.

https://doi.org/10.1182/blood-2002-11-3381

Published: 2003

Journal Articles

Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a single cell level

Zlatko Dembic, John-Arne Røttingen, Jérôme Dellacasagrande, Karl Schenck, Bjarne Bogen

Blood (2001) 97 (9): 2808–2814.

https://doi.org/10.1182/blood.V97.9.2808

Published: 2001

NARROW

Characterizing the Multiple Myeloma Bone Marrow Microenvironment at the Single-Cell Level in a Preclinical Model

IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model

Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of Multiple Myeloma

Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model

Targeted Remodeling of the Tumor Microenvironment Via Mechanical Stimulation Defines a Novel Therapeutic Strategy in Myeloma Bone Disease

CSF1R-Inhibition and Reduction of Macrophages Delays Multiple Myeloma Growth in a Non-T-Cell-Dependent Manner

Targeting Notch and Hedgehog Embryonic Signaling Pathways Has Potent Anti-Tumor Activity in Myeloma and Is Effective in Myeloma Bone Disease.

Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice

Lymphoma invisibility–vaccination–attack?

Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences

Therapeutic effect of idiotype-specific CD4 + T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies

Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a single cell level

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only